Pamela Phelps
Primary Care · Morgantown, KYNPI 1548599459
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations.
Across 161 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$328
- Pfizer$233
- Novo Nordisk$203
- GSK$159
- Bayer$143
- Axsome Therapeutics, Inc.$138
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,701100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 23 | $328 |
| Pfizer | 13 | $233 |
| Novo Nordisk | 14 | $203 |
| GSK | 9 | $159 |
| Bayer | 9 | $143 |
| Axsome Therapeutics, Inc. | 2 | $138 |
| Abbott | 9 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $111 |
| Novartis | 6 | $108 |
| Phathom Pharmaceuticals, Inc. | 5 | $106 |
| AstraZeneca | 7 | $103 |
| Kowa Pharmaceuticals America, Inc. | 6 | $96 |
| AbbVie | 4 | $66 |
| Insulet Corporation | 4 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Baxter Healthcare | 3 | $57 |
| Johnson & Johnson | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Exact Sciences | 3 | $43 |
| Phadia US Inc. | 2 | $42 |
| Mylan Specialty L.p. | 2 | $34 |
| Lilly USA, LLC | 2 | $31 |
| Viatris Specialty LLC | 2 | $31 |
| CMP Pharma, Inc. | 2 | $30 |
| Nabriva Therapeutics, PLC | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Astellas Pharma US Inc | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Verona Pharma, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
| Merck | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$116
How this compares
$2,701 in reported general payments places this provider in the 85th percentile of 80 primary care providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $60,263 |
| EliquisApixaban | 54 | $57,839 |
| JanuviaSitagliptin Phosphate | 50 | $40,164 |
| MounjaroTirzepatide | 27 | $31,652 |
| FarxigaDapagliflozin Propanediol | 26 | $18,766 |
| JardianceEmpagliflozin | 16 | $17,353 |
| LinzessLinaclotide | 21 | $15,614 |
| XareltoRivaroxaban | 14 | $14,636 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $13,015 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $12,490 |
| Spiriva RespimatTiotropium Bromide | 12 | $11,089 |
| MovantikNaloxegol Oxalate | 17 | $8,505 |
| Repatha SyringeEvolocumab | 12 | $6,481 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,349 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 235 | $4,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $203 | $60,26353 claims |
| PfizerEliquis | $233 | $57,83954 claims |
| MerckJanuvia | $12 | $40,16450 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $103 | $35,60460 claims |
| Lilly USA, LLCMounjaro | $31 | $31,65227 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $11 | $28,44128 claims |
| AbbVieLinzess, Synthroid | $66 | $16,05934 claims |
| Johnson & JohnsonXarelto | $50 | $14,63614 claims |
| GSKTrelegy Ellipta | $159 | $13,01511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 80 primary care providers in Kentucky.
Other primary care in Morgantown
- Jessica GoettlLouisville$59K
- Angela ClarkBowling Green$10K
- Tara CoyleShelbyville$7K
- Heather AdamsLexington$7K
- Bridget McKinleyElizabethtown$6K
- Tracy DarlingtonCrestview Hills$6K
- Reagen LoughranLondon$6K
- Jeryl PittmanRichmond$6K
- Samantha FraleyPrestonsburg$3K
- Kayla HensonBenton$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.